The completion will be marked by two customer events, on December 1 and December 6
Catalent has completed the expansion of its clinical supply facility in the Waigaoqiao Free Trade Zone (FTZ) in Shanghai, China.
The project has seen the site increase by approximately 30,000 sqft (approximately 2,800 sqm), which has allowed the installation of additional refrigerated (between 2 and 8 degrees Celsius) and deep-frozen (between minus 70 and minus 90 degrees Celsius) storage, and secondary packaging capabilities to be expanded. The completion will be marked by two customer events, on December 1 and December 6, where members of Catalent’s senior management team will be showcasing the facilities at the site and hosting workshops on clinical supply management and new GMP policies.
These additional capabilities increase the site’s ability to support clinical trials for advanced therapeutics, which often require specialised storage and handling capabilities
The Waigaoqiao facility is one of two clinical supply facilities that Catalent operates in Shanghai, the other being in Tangzhen, outside the FTZ. Together, they provide sponsors with optimised supply solutions for studies being undertaken in China, and through Catalent’s extensive network, the Asia-Pacific region and globally. These include clinical supply management, comparator sourcing, FastChain demand-led supply, primary and secondary packaging, storage, and global distribution, as well as clinical returns and destruction.
“China is the fastest growing clinical trials market in the Asia-Pacific region, and Catalent continues to invest and expand its facilities and services to offer reliable, flexible, and integrated support to customers,” said Tracey Clare, General Manager, APAC Operations, Catalent. “These additional capabilities increase the site’s ability to support clinical trials for advanced therapeutics, which often require specialised storage and handling capabilities."